PTCT - חוב כולל להון PTC Bio

This chart illustrating the historical change in the total debt-to-equity ratio for PTC Therapeutics, Inc. (PTCT) is 0.00. PTC Therapeutics, Inc. (PTCT) develops therapies for rare brain pathologies, protecting its research through patents and government grants. The business currently relies on internal portfolio development, limiting itself to the selective transfer of rights for early-stage molecules. The high cost of specialized drug delivery remains a critical factor in ensuring the quality of treatment.

This ratio measures the extent to which the balance sheet structure depends on borrowed funds relative to equity, signaling financial stability risks and potential liquidity gaps to the investor. For PTC Therapeutics, Inc. (PTCT), a low debt load is critical for maintaining costly temperature-controlled logistics and the distribution of orphan drugs, a fact clearly reflected in the total debt-to-equity proportion on the GURU.Markets platform.